2024 Results
Executive Summary
| Goal | Target | Actual | Achievement |
|---|---|---|---|
| Revenue | €870,369 | €410,787 | 47% |
| New Markets | 2 | 2 | 100% |
| NPS | 70% | 73% | 104% |
Performance was affected by the lack of a business development team and the founding team's focus on compliance audits and the financing round. This caused slower-than-expected progress on revenue targets but allowed for exceeded performance on market expansion and customer satisfaction.
Revenue
Target: €870,369 (2.5x growth) Actual: €410,787 (118% YoY growth) Achievement: 47%
Key factors:
- Business development team not yet in place
- Founding team bandwidth split between sales, compliance audits, and financing round
- Longer-than-expected sales cycles in enterprise healthcare
Review the invoice by segment section for detailed breakdown.
Market Expansion
Target: 2 new markets Actual: 2 markets Achievement: 100%
New markets entered:
- Germany — Direct sales
- Hong Kong — Direct sales
Brazil contract signed in late 2024 (partnership model), with operations starting in 2025.
Global presence (2024): Spain, France, Germany, Sweden, Hong Kong
Key wins:
- 8 new contracts closed
- First public tender secured (SESPA)
Customer Satisfaction
Target: NPS 70% Actual: NPS 73% Achievement: 104% ✓
Exceeded target by 3 percentage points, reflecting enhanced customer satisfaction and loyalty through improved support processes and product reliability.